Intervention not reported
Deep surgical site infection at 30 days or 90 days, or time points reported by study authors · adults with open long bone fractures; study in the review included only Gustilo II open tibia fractures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Delayed or non‐union at time points reported by study authors · adults with open long bone fractures; study in the review included only Gustilo II open tibia fractures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Unplanned operations at 12 months · adults with open long bone fractures; study in the review included only Gustilo II open tibia fractures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events: superficial infection · adults with open long bone fractures; study in the review included only Gustilo II open tibia fractures
It is very uncertain whether the intervention changes adverse events: superficial infection (very low certainty).
1 finding from 1 review
Intervention not reported
Return to work by 12 months · adults with open long bone fractures; study in the review included only Gustilo II open tibia fractures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Limb function at 6 or 12 months · adults with open long bone fractures of the upper and lower limbs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
HRQoL at 6 or 12 months · adults with open long bone fractures of the upper and lower limbs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Paina Scale: 0 to 100, 0 is no pain · people with degenerative knee disease (osteoarthritis including degenerative meniscal tears)
1 finding from 1 review
Intervention not reported
Knee functiona Scale: 0 to 100, 100 is best function · people with degenerative knee disease (osteoarthritis including degenerative meniscal tears)
1 finding from 1 review
Intervention not reported
Knee‐specific health‐related quality of lifea Scale: 0 to 100, 100 is best quality of life · people with degenerative knee disease (osteoarthritis including degenerative meniscal tears)
1 finding from 1 review
Intervention not reported
Participant‐reported success Last · people with degenerative knee disease (osteoarthritis including degenerative meniscal tears)
The intervention showed no clear difference in participant‐reported success Last (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse eventsLast · people with degenerative knee disease (osteoarthritis including degenerative meniscal tears)
The intervention showed no clear difference in serious adverse eventsLast (low certainty).
1 finding from 1 review
Intervention not reported
Total adverse events Last · people with degenerative knee disease (osteoarthritis including degenerative meniscal tears)
The intervention showed no clear difference in total adverse events Last (low certainty).
1 finding from 1 review
Overall survival: Median length of · women with advanced EOC after PDS
Small‐volume residual disease (SVRD) < 1 cm probably leads to higher overall survival: Median length of compared with NMRD (moderate certainty).
1 finding from 1 review
Progression‐free survival · women with advanced EOC after primary IDS
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival: Median length of · women with advanced EOC after primary IDS
It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes overall survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (very low certainty).
1 finding from 1 review
Progression‐free survival · women with advanced EOC after primary IDS
It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes progression‐free survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (very low certainty).
1 finding from 1 review
Overall survival: Median length of · women with advanced EOC after primary IDS
It is very uncertain whether residual disease (RD) > 0 cm changes overall survival: Median length of compared with NMRD (very low certainty).
1 finding from 1 review
Progression‐free survival · women with advanced EOC after primary IDS
It is very uncertain whether residual disease (RD) > 0 cm changes progression‐free survival: Median length of compared with NMRD (very low certainty).
1 finding from 1 review
Progression‐free survival · women with advanced EOC after PDS
Small‐volume residual disease (SVRD) < 1 cm probably leads to higher progression‐free survival: Median length of compared with NMRD (moderate certainty).
1 finding from 1 review